论文部分内容阅读
目的:探讨中晚期肝细胞癌(HCC)采用肝动脉化疗栓塞联合索拉菲尼治疗的临床疗效。方法:按照随机数字表法将2012年3月-2014年3月我院收治的中晚期HCC患者分为两组,对照组行肝动脉化疗栓塞术治疗,观察组在对照组基础上联合索拉菲尼治疗。比较两组的疗效,毒副反应及远期生存率。结果:观察组患者治疗后6个月的临床疗效优于对照组,差异有统计学意义(Z=-2.316,P=0.021),观察组有效率52.50%,高于对照组的28.21%,差异有统计学意义(x2=4.837,P=0.028)。治疗后观察组手足皮肤反应和口腔黏膜炎症的发生率为22.50%、25.00%,分别高于对照组的5.13%、5.13%,差异有统计学意义(P<0.05)。观察组6、12个月的生存率为95.00%、85.00%,分别高于对照组的79.49%、64.10%,差异有统计学意义(P<0.05)。结论:肝动脉化疗栓塞联合索拉菲尼治疗HCC具有疗效好、明显延长患者生存时间的特点,临床有重要的参考价值。
Objective: To investigate the clinical efficacy of transcatheter arterial chemoembolization combined with sorafenib in advanced hepatocellular carcinoma (HCC). Methods: According to the random number table method, patients with advanced stage HCC who were treated in our hospital from March 2012 to March 2014 were divided into two groups. The control group received hepatic artery chemoembolization. The observation group was combined with sora Finney treatment. The curative effect, side effects and long-term survival rate of the two groups were compared. Results: The clinical efficacy of the observation group was better than that of the control group at 6 months after treatment (Z = -2.316, P = 0.021). The observation group had an effective rate of 52.50%, which was higher than that of the control group (28.21%), There was statistical significance (x2 = 4.837, P = 0.028). The incidences of hand, foot and skin reaction and oral mucosal inflammation in the observation group after treatment were 22.50% and 25.00%, respectively, which were 5.13% and 5.13% higher than those in the control group respectively. The difference was statistically significant (P <0.05). The survival rates of observation group at 6 and 12 months were 95.00% and 85.00%, respectively, which were significantly higher than 79.49% and 64.10% respectively in control group (P <0.05). Conclusion: Hepatic arterial chemoembolization combined with sorafenib in treatment of HCC has good curative effect and significantly prolongs the survival time of patients. It has important clinical value.